512 Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Grand Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.56 |
| 52 Week High | HK$5.62 |
| 52 Week Low | HK$3.17 |
| Beta | 0.71 |
| 11 Month Change | -12.31% |
| 3 Month Change | 4.83% |
| 1 Year Change | 1.33% |
| 33 Year Change | -23.10% |
| 5 Year Change | 0.22% |
| Change since IPO | 9.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 512 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -1.7% | -7.2% | -0.6% |
| 1Y | 1.3% | -5.9% | 14.2% |
Return vs Industry: 512 exceeded the Hong Kong Pharmaceuticals industry which returned -2.9% over the past year.
Return vs Market: 512 underperformed the Hong Kong Market which returned 15% over the past year.
Price Volatility
| 512 volatility | |
|---|---|
| 512 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 512 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 512's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 10,775 | Chao Zhou | www.grandpharm.com |
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products.
Grand Pharmaceutical Group Limited Fundamentals Summary
| 512 fundamental statistics | |
|---|---|
| Market cap | HK$15.97b |
| Earnings (TTM) | HK$2.41b |
| Revenue (TTM) | HK$10.59b |
6.6x
P/E Ratio1.5x
P/S RatioIs 512 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 512 income statement (TTM) | |
|---|---|
| Revenue | HK$10.59b |
| Cost of Revenue | HK$4.34b |
| Gross Profit | HK$6.25b |
| Other Expenses | HK$3.84b |
| Earnings | HK$2.41b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 59.00% |
| Net Profit Margin | 22.75% |
| Debt/Equity Ratio | 28.1% |
How did 512 perform over the long term?
See historical performance and comparison